share_log

Enzo Therapeutics Awarded U.S. Patent 10,945,971 'Sphingosine kinase type 1 inhibitors and uses thereof'

Enzo Therapeutics Awarded U.S. Patent 10,945,971 'Sphingosine kinase type 1 inhibitors and uses thereof'

恩佐治療公司獲得美國專利10,945,971“鞘氨醇激酶1型抑制劑及其用途”
Benzinga Real-time News ·  2021/03/16 19:16

Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management. These compounds are applicable to treating ischemic diseases such as myocardial infarction and stroke.

本發明提供了在許多應用、適應症和疾病中有用的鞘氨醇激酶I型抑制劑，以及用於監測藥代動力學和患者管理的抑制劑。這些化合物適用於治療心肌梗死和中風等缺血性疾病。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論